SFA
GRCE

Sequoia Financial Advisors’s Grace Therapeutics GRCE Stock Holding History

Sequoia Financial Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-208
Closed -$6K – 490
2021
Q1 		$6K Hold
208
– – ﹤0.01% 447
2020
Q4 		$3K Hold
208
– – ﹤0.01% 418
2020
Q3 		$2K Hold
208
– – ﹤0.01% 388
2020
Q2 		$5K Hold
208
– – ﹤0.01% 366
2020
Q1 		$4K Buy
+208
New +$7.37K ﹤0.01% 365

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sequoia Financial Advisors's GRCE Position: Q2 2021 in Review

Sequoia Financial Advisors sold out of Grace Therapeutics (GRCE) in Q2 2021, closing a stake of 208 shares — an estimated $6K sold.

Sequoia Financial Advisors first reported a position in GRCE in Q1 2020 and held it in 5 quarters. The position peaked at $6K in Q1 2021. 26 funds tracked by Wall St. Rank hold GRCE as of Q2 2021.

  • Sequoia Financial Advisors reported no remaining Grace Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sequoia Financial Advisors sold 208 Grace Therapeutics shares in Q2 2021, an estimated $6K.
  • Sequoia Financial Advisors first reported a position in Grace Therapeutics in Q1 2020 and held it in 5 quarters.
  • Sequoia Financial Advisors's Grace Therapeutics position peaked at $6K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2021.

Based on Sequoia Financial Advisors's 13F filing for Q2 2021, filed 27 Jul 2021.